MDx/CDx Focus: CHMP Positive Opinion on Exelixis' Cometriq; Kalydeco in R117H-Mutated CF | GenomeWeb

Originally published Dec. 23.

EU's CHMP Issues Positive Opinion Exelixis' Cometriq for Medullary Thyroid Cancer

The European Committee for Medicinal Products for Human Use granted a positive opinion of the Exelixis' marketing authorization application for Cometriq (cabozantinib), which the firm is developing as a treatment for progressive, unresectable locally advanced, or metastatic medullary thyroid carcinoma.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.